Miki Sudo and Nick Wehry attended PAX2020, a video game convention in Boston, to promote the new game Bite the Bullet. Other competitive eaters in the game include Bob Shoudt, Naader Reda, Yasir Salem, Crazy Legs Conti. Matt Stone, LA Beast and more. (Is this the first project with both MLE and non-MLE competitors? The only other one I can think of the Amazing Race team of Joey Chestnut and retired Tim Janus.)

March 1, 2020 at 12:09 am by ojrifkin · More posts about:Boston, Miki Sudo, Nick Wehry, Video Games | Permalink * Comments (10)

10 Comments »

  1. Anonymous said

    March 1, 2020 @ 3:15 am

    Lame

  2. anonymous said

    March 1, 2020 @ 6:17 am

    LA Beast does not want his name or image affiliated with MLE. Expect some sort of backlash when word gets back to him

  3. Anonymous said

    March 1, 2020 @ 8:21 am

    Don’t the makers of this game have to get permission to use the eaters images and information?

  4. anonymous said

    March 1, 2020 @ 9:32 am

    speaking of Janus does he realize the foreign country he is currently living in is also contaminated with corona virus Good luck on that one

  5. Johnson said

    March 1, 2020 @ 9:32 am

    At least MLE can’t send L.A. Beast threatening letters from their corporate lawyer…
    or harassing phone calls and emails from Dave Bear requesting his address and other info about his personal projects. Fook MLE. They better send legal notices to all MLE players in this game…Muahahaha

  6. anonymous said

    March 1, 2020 @ 1:41 pm

    And this was all over LA Beast and Furious Pete goofing on Lermans butter record on youtube . I heard sheas went berserk when the both of them make mockery of it . They did not find it amusing at all

  7. Anonymous said

    March 1, 2020 @ 1:55 pm

    Why do most assume that the eaters in MLE have not gotten permission to participate in contests and video games and whatevers?

  8. Anonymous said

    March 1, 2020 @ 1:56 pm

    Janus did not go to Korea to live in a cave. Of course he knows. You are filled with hope that he will get sick. That is sicko.

  9. Anonymous said

    March 2, 2020 @ 1:32 am

    821 yes they do

  10. Games all day said

    March 2, 2020 @ 8:12 am

    I wonder who the fink is gonna spread the wealth to next. Keep it in the MLE family or spread to the independent losers? Not much up for grabs there.

  11. nrisoulmate.com said (Comment pending approval)

    October 25, 2025 @ 6:17 am

    Albicans, which are often liable for infections in people with inflammatory circumstances.
    For those with situations like irritable bowel syndrome (IBS) or
    persistent inflammation of the gastrointestinal
    tract, KPV peptide can supply substantial aid by reducing symptoms like bloating,
    cramping, and discomfort. The peptide can penetrate skin obstacles making it fascinating for dermatological research.
    Research has proven topical formulations can deliver efficient concentrations to focus on tissues whereas
    minimizing systemic publicity. Research on the structural
    model present that KPV’s small measurement allows it to penetrate mobile membranes and attain intracellular targets.
    This is different from larger peptides that may face drug delivery challenges in research purposes.
    Primarily Based on the mechanism of action you simply
    noticed, it must be clear how and why KPV addresses persistent
    irritation and restores the physique to a state of homeostasis.

    We perceive the significance of reliable elements for creating groundbreaking health options.
    Explore the potential of KPV peptide to enhance your product line and contribute to higher well being outcomes.
    Purchase KPV peptide from a trusted source to ensure the quality and effectiveness your prospects expect.

    KPV is a tripeptide derived from the alpha-melanocyte-stimulating
    hormone (?-MSH) sequence, studied for its function in modulating
    inflammatory signaling pathways. It is usually used in laboratory research to discover mobile
    responses related to irritation, immune modulation, and
    tissue homeostasis. Researchers investigate KPV for its
    potential effects on inflammatory cascade regulation in managed experimental settings.

    The peptide’s selectivity is an enormous advantage over traditional anti inflammatory compounds.
    While standard approaches often suppress
    immune responses broadly, research shows KPV supports
    immune perform whereas concentrating on inflammatory pathways.
    This is fascinating for researchers finding out illness situations where immune
    modulation rather than suppression is useful. The molecular construction of KPV comes from the C-terminal region of ?
    melanocyte stimulating hormone (alpha MSH), a bigger peptide produced in the body’s regulatory techniques.
    Analysis exhibits this particular amino acid sequence is secure and has
    important anti-inflammatory effects in lab settings. The terminal lysine
    part appears to be essential for the compound’s bioactivity as modifications to this region can change
    the peptide’s practical properties.
    Moreover, %E considerably decreased the ulcer wound space and accelerated re-epithelization within 3–5 days. On day 5, rats in each group were sacrificed and the gingival ulcer wounds had been collected for histopathological morphology evaluation. In the management group, a considerable quantity of granulation tissue was infiltrated within the mucosal epithelium, the floor of which was coated with necrotic tissue. By distinction, rats handled with PPP_2%E, KPV SOL or %E exhibited much less granulation tissue or inflammatory cell infiltration. Nonetheless, after treatment with DEX, the inflammatory cell infiltration was even worse than within the PPP_2%E
    or KPV SOL group.
    Furthermore, macrophage activation by MTII led to an increase in cAMP accumulation, which was attenuated by SHU9119, whereas KPV failed to extend cAMP.
    The anti-inflammatory properties of KPV have been additionally evident in IL-1?-induced peritonitis inflammation and in mice with a nonfunctional MC1-R (recessive yellow e/e mice).
    KPV peptide is a short chain of amino acids (Ketoprolyl-valyl-prolyl) that has proven potential as a remedy for persistent pain and
    irritation.
    It’s increasingly studied for its potential to manage chronic
    irritation, restore intestine integrity, and speed up skin healing.
    They discovered that the C-terminal tripeptide,
    KPV, retained nearly the entire anti-inflammatory activity of the
    full 13-amino-acid hormone. Subsequent research by groups all over the world has confirmed these findings and expanded on them.

    Main analysis efforts have centered on using KPV in animal fashions
    of inflammatory bowel illness, where it confirmed a
    outstanding ability to heal the infected colon. Different intensive analysis, led by figures like Dr.
    Thomas Luger, has investigated its topical use for inflammatory pores and skin illnesses, demonstrating its ability to penetrate the pores and skin and calm irritation domestically.

    KPV and BPC-157 each heal, but KPV focuses on anti-inflammatory results and immune
    modulation. KPV derives from alpha melanocyte stimulating hormone and inhibits inflammatory pathways.

    This compliments work by Getting et al [27] which demonstrated a central position for
    MC3R in suppressing leucocyte mediated airway irritation. KPV affords the benefit that its actions
    don’t seem like receptor mediated and its construction may
    be potentially modulated to improve its targeting to a minimal of
    one explicit pathway or another. Furthermore its small size and aqueous solubility
    mean that it might be delivered in nebulised type to
    the lung where our knowledge shows it’s capable
    of mediating anti-inflammatory results in lung epithelia.

    The suppression of MMP activity is particularly notable as
    this family of proteases performs a major role in immune signalling and lung
    remodelling in diversified types of inflammatory and cancerous lung diseases [reviewed 29].
    Taken as a whole, this work suggests that KPV and MC3R agonists characterize perfect candidates
    for the suppression of the early stages of irritation in airway epithelia.
    Current studies have demonstrated the effectiveness of KPV
    peptide in managing ulcerative colitis, a chronic inflammatory bowel
    disease (IBD).

RSS feed for comments on this post · TrackBack URI

Leave a Comment

Log in | Register | Comments by users who have not logged in will be held for approval